Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
Published Nov 23, 2016
177 pages — Published Nov 23, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectiou

  
Source:
Document ID
GMDHC8694IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Cytomegalovirus (HHV-5) Infections Overview131
Therapeutics Development142
  Pipeline Products for Cytomegalovirus (HHV-5) Infections Overview141
  Pipeline Products for Cytomegalovirus (HHV-5) Infections Comparative Analysis151
Cytomegalovirus (HHV-5) Infections Therapeutics under Development by Companies162
Cytomegalovirus (HHV-5) Infections Therapeutics under Investigation by Universities/Institutes182
Cytomegalovirus (HHV-5) Infections Pipeline Products Glance204
  Late Stage Products201
  Clinical Stage Products211
  Early Stage Products221
  Unknown Stage Products231
Cytomegalovirus (HHV-5) Infections Products under Development by Companies243
Cytomegalovirus (HHV-5) Infections Products under Investigation by Universities/Institutes272
Cytomegalovirus (HHV-5) Infections Companies Involved in Therapeutics Development2927
  Adicet Bio, Inc.291
  AIMM Therapeutics BV301
  Astellas Pharma Inc311
  Atara Biotherapeutics Inc321
  AvidBiotics Corp331
  Biotest AG341
  Chimerix Inc351
  China Biologic Products Inc361
  CyTuVax BV371
  Fate Therapeutics Inc381
  GlaxoSmithKline Plc391
  Hookipa Biotech AG401
  Kadmon Corp LLC411
  Laboratoires Thea SA421
  Merck &Co Inc431
  Microbiotix Inc441
  Mymetics Corp451
  Novartis AG461
  Pfizer Inc471
  Phoenix Biotechnology Inc481
  Savoy Pharmaceuticals, Inc.491
  Sigma-Tau SpA501
  Themis Bioscience GmbH511
  Trellis Bioscience Inc521
  Vakzine Projekt Management GmbH531
  VBI Vaccines Inc541
  Vical Inc551
Cytomegalovirus (HHV-5) Infections Therapeutics Assessment5610
  Assessment by Monotherapy Products561
  Assessment by Combination Products571
  Assessment by Target582
  Assessment by Mechanism of Action602
  Assessment by Route of Administration622
  Assessment by Molecule Type642
Drug Profiles6690
  AIC-387 Drug Profile661
  AIC-476 Drug Profile671
  AIC-813 Drug Profile681
  AL-18 Drug Profile691
  Antibody for Human Cytomegalovirus Infection Drug Profile701
  ASP-0113 Drug Profile713
  brincidofovir Drug Profile7414
  BT-084 Drug Profile881
  Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections Drug Profile891
  Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile901
  Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile911
  Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile921
  Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile931
  Cellular Immunotherapy for Cytomegalovirus Infections and GBM Drug Profile941
  Cellular Immunotherapy for Infectious Disease Drug Profile951
  Cellular Immunotherapy for Infectious Diseases Drug Profile961
  Cellular Immunotherapy for Viral Infections Drug Profile971
  Cellular Immunotherapy for Viral Infections Post-HSCT Drug Profile981
  Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections Drug Profile991
  Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile1002
  Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile1021
  Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile1031
  CMX-669 Drug Profile1041
  CSJ-148 Drug Profile1051
  CyMVectin Drug Profile1062
  cytomegalovirus (virus like particle) vaccine Drug Profile1081
  Cytomegalovirus (virus like particle) vaccine Drug Profile1091
  Cytomegalovirus vaccine Drug Profile1101
  Cytomegalovirus vaccine Drug Profile1111
  Cytomegalovirus vaccine Drug Profile1121
  filociclovir Drug Profile1132
  ganciclovir Drug Profile1151
  Gene Therapy for Cytomegalovirus Infections Drug Profile1161
  HB-101 Drug Profile1171
  letermovir Drug Profile1183
  maribavir Drug Profile1213
  MBX-2168 Drug Profile1241
  Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections Drug Profile1251
  Monoclonal Antibody for Cytomegalovirus Infections Drug Profile1261
  Monoclonal Antibody to Agonize LTbR for CMV Infection Drug Profile1271
  Pentamer Drug Profile1281
  Peptides to Inhibit Heparan Sulfate for HHV-5 Infections Drug Profile1291
  PepVax Drug Profile1302
  ProTmune Drug Profile1322
  PTX-3 Drug Profile1341
  RBT-301 Drug Profile1351
  Recombinant Peptide for Infectious Diseases Drug Profile1361
  Recombinant Protein for CMV Drug Profile1371
  RKP-00156 Drug Profile1381
  Small Molecule for Cytomegalovirus Drug Profile1391
  Small Molecules for CMV Infections Drug Profile1401
  Small Molecules for CMV infections and Cancer Drug Profile1411
  Small Molecules to Activate Sirtuin for Viral Infections Drug Profile1421
  Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections Drug Profile1431
  Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases Drug Profile1441
  Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections Drug Profile1451
  Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease Drug Profile1461
  Triplex Drug Profile1472
  TRL-345 Drug Profile1491
  V-160 Drug Profile1501
  VBI-1501A Drug Profile1512
  Viralym-C Drug Profile1531
  Viroprev Drug Profile1541
  VPM-2001 Drug Profile1551
Cytomegalovirus (HHV-5) Infections Dormant Projects1565
Cytomegalovirus (HHV-5) Infections Discontinued Products1611
Cytomegalovirus (HHV-5) Infections Product Development Milestones16214
  Featured News &Press Releases1621
    Nov 03, 2016: Atara Bio Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 20161621
    Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood1621
    Oct 27, 2016: Results from Shire Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant1632
    Oct 19, 2016: Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint1651
    Oct 11, 2016: Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems1651
    Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients1661
    Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate1661
    Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress1671
    Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review1681
    Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine1681
    Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate1691
    Feb 20, 2016: Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings1702
    Dec 28, 2015: Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir1721
    Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 20151731
    Oct 22, 2015: Chimerix Initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients1742
Appendix1762
  Methodology1761
  Coverage1761
  Secondary Research1761
  Primary Research1761
  Expert Panel Validation1761
  Contact Us1761
  Disclaimer1771

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016" Nov 23, 2016. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cytomegalovirus-HHV-5-Infections-Pipeline-Review-H2-2016-2088-16869>
  
APA:
Global Markets Direct - Market Research. (2016). Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016 Nov 23, 2016. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cytomegalovirus-HHV-5-Infections-Pipeline-Review-H2-2016-2088-16869>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.